The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
about
Current status of immunotherapySignaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated MacrophagesInterleukin-35: Expanding Its Job ProfileDendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancerRegulatory T cell: a protection for tumour cellsImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerThe role of regulatory T cells in cancer immunologyHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyTumor infiltrating lymphocytes in ovarian cancerTargeted immune therapy of ovarian cancerMathematical modeling of Interleukin-35 promoting tumor growth and angiogenesisEpigenetic control of the foxp3 locus in regulatory T cellsFavorable prognostic value of SOCS2 and IGF-I in breast cancer.Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging.Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancerSystematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factorsAutologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg).Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironmentA Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression.Ovarian cancer immunotherapy: opportunities, progresses and challengesDisruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity.Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer.Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinomaSPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer.Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.Retinoblastoma binding protein 2 (RBP2) promotes HIF-1α-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.Expression of THOP1 and its relationship to prognosis in non-small cell lung cancer.Optimal population of FoxP3+ T cells in tumors requires an antigen priming-dependent trafficking receptor switchBTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosisDepletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responsesImmune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.Inherited variants in regulatory T cell genes and outcome of ovarian cancer.Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.Tregs and rethinking cancer immunotherapy.
P2860
Q26773314-A83D29E7-F99C-4B12-8F71-51FBD1F389B8Q26783748-5E2378DE-E39E-4791-B3E8-08D07077ABCAQ26829619-AEB3B267-BA6A-4EDA-B1E6-E589FB0B398DQ26861293-A7102326-972D-4F37-9CEF-0C01F6DAC655Q26991447-C1FA9BCB-8D47-435E-AE67-88BA7842E0A2Q26996829-EC7A8FBF-F9A2-40F7-B52B-22EBFE6E8138Q27006663-CBCAAE73-0DE5-46BF-A8EA-155EA00009C0Q27021570-9D69C85E-D46A-4B0A-9779-8197C4F74E67Q27021878-74A53DA3-1EEF-4CDF-8057-A222EA5FC24FQ28082828-0CB32B5A-623C-499F-AA90-720C7172B130Q28544606-350F92EB-FE2A-4548-9BD8-B75D2BC1E330Q33273617-08615D4D-382F-43BD-B04C-06CB1D8AC9DAQ33291671-858B95A2-F075-48C0-9028-C837598931FBQ33357295-80720FF1-F511-49BF-979A-B1768D158417Q33377058-5C54D38C-265E-461D-AEB4-4FC39963E563Q33459037-2206FF82-5D18-4EF7-8158-75EF8F568B7FQ33482453-5AA81EED-3D87-4CD0-BBDF-2B5407716BBCQ33488520-6888B690-9663-4305-9014-BCA16340E854Q33584997-0380BF59-AB17-4128-9BC2-29371DDBDDAFQ33638975-1395BD11-B124-4847-BBFF-5BA9315C1492Q33641504-7A8D5B2A-7F50-4694-8730-3E65F0F434C3Q33671344-A10E9496-4579-46E3-B790-941322AD3663Q33694988-2A19FA98-3421-4224-8C41-63BF3868EF81Q33702218-B1FA237B-D45A-4B05-BDC3-C351AEB224CFQ33772507-32193C45-2126-4C12-BEB6-6DA4F7D53F5EQ33783092-B10288C6-EF42-4F36-B347-E42C11D5A5ADQ33849500-635C8A78-EDF6-4BEF-958B-854023F82C55Q33865610-8241BDBB-867A-4FAE-B2A6-18CE6EF542E8Q33983083-B6C237D1-651D-470C-B090-1B59B762BFFBQ34007762-61260B85-A8FD-4619-B3D9-A4A40338EE8BQ34020594-C8D43899-68B2-4899-B4D2-AE106E3D2E04Q34097528-56E1AE86-FE48-4872-8EB8-0393B4797CB6Q34122661-4AD5CFB1-402F-4059-85EC-93616BCD09E6Q34146406-E28630D2-0499-4924-8E81-6F2FAA1D7F99Q34299655-CC305680-AF2F-4014-BAD2-DA350DAE6A2CQ34451999-44FD4F77-FB42-4829-91BD-525B24CF017BQ34557233-8A2FAB35-710F-4E1F-A426-B1E24B1F27C7Q34575290-E3EF393E-B6EA-4563-B360-D7F2AF3F4E57Q34610483-CFC8D72C-8844-4819-B8BD-CDE45FA6D37CQ34625147-E32BAA75-D619-40F8-B1E5-68A1FA071AE9
P2860
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The expression of the regulato ...... r prognosis in ovarian cancer.
@en
The expression of the regulato ...... r prognosis in ovarian cancer.
@nl
type
label
The expression of the regulato ...... r prognosis in ovarian cancer.
@en
The expression of the regulato ...... r prognosis in ovarian cancer.
@nl
prefLabel
The expression of the regulato ...... r prognosis in ovarian cancer.
@en
The expression of the regulato ...... r prognosis in ovarian cancer.
@nl
P2093
P1476
The expression of the regulato ...... or prognosis in ovarian cancer
@en
P2093
Alain G Zeimet
Anna M Wolf
Christian Marth
Dominik Wolf
Eberhard Gunsilius
Elisabeth Muller-Holzner
Guenther Gastl
Martina Deibl
P304
P356
10.1158/1078-0432.CCR-05-1244
P407
P577
2005-12-01T00:00:00Z